Low-intensity shockwave therapy (Li-ESWT) is one of the most evidence-supported non-invasive treatments for vasculogenic erectile dysfunction. By delivering acoustic energy to penile tissue, it stimulates angiogenesis — the formation of new blood vessels — and breaks down the micro-plaque that restricts blood flow. Multiple clinical studies have demonstrated significant improvements in erectile function, and the treatment is completely non-invasive with no systemic side effects.
How Shockwave Therapy Works
Low-intensity shockwaves are acoustic pressure waves delivered to tissue via a handheld device. When applied to penile tissue, these waves trigger several biological responses: they stimulate the release of angiogenic growth factors (particularly VEGF), activate endothelial progenitor cells that form new blood vessels, break down micro-plaque deposits in penile arteries, and stimulate the release of nitric oxide — a key mediator of erectile function.
The Clinical Evidence
Li-ESWT for erectile dysfunction has been studied in multiple randomized controlled trials. A 2019 meta-analysis of 14 studies found significant improvements in erectile function scores, with effects lasting up to 12 months after treatment. The treatment appears most effective for vasculogenic ED — the most common form — and for men who respond to PDE5 inhibitors (Viagra, Cialis) but want a more lasting solution.
The Treatment Protocol
A standard shockwave therapy protocol consists of 6–12 sessions, typically performed twice weekly over 3–6 weeks. Each session takes approximately 20–30 minutes and requires no anesthesia. There is no downtime, and most patients return to normal activities immediately.
Combining with the P-Shot®
Sound wave therapy and the P-Shot® work through complementary mechanisms — shockwave therapy stimulates angiogenesis from the outside, while PRP stimulates it from within the tissue. When combined, they produce a synergistic effect that significantly outperforms either treatment alone. At DrBeautyMD, we frequently recommend this combination for patients with moderate to severe vasculogenic ED.
